Value through Innovation21 October 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 next
22.05.2012

Boehringer Ingelheim announces positive phase II results for once-daily tiotropium in asthma

- For Media outside the U.S., Canada and UK
21.05.2012

Boehringer Ingelheim’s once-daily bronchodilator olodaterol* successfully completes Phase II clinical trial program in COPD

- For Media outside the U.S., Canada and UK
29.04.2012

Switching to TWYNSTA® allows patients with uncontrolled hypertension on monotherapy to rapidly reach their blood pressure goals

- For Non-US and Non-UK Healthcare Media Only
24.04.2012

Boehringer Ingelheim on growth path - Successful 2011 financial year

20.04.2012

GLORIATM-AF Registry Program investigating use of antithrombotic therapy in 56,000 patients with atrial fibrillation at risk of stroke announced

- For non-US, UK & Canadian Media
19.04.2012

Viral cure achieved without interferon in up to 82% of hepatitis C patients (GT-1a & -1b*)

- For media outside of the U.S.A. only
19.04.2012

First ever data investigating interferon-free treatment in hepatitis C patients who have liver cirrhosis shows high viral cure rate

- For media outside of the U.S.A. only
18.04.2012

Leading medical and patient organisations join forces to improve stroke prevention in atrial fibrillation

- For NON-US and NON-UK Media Only
18.04.2012

Dabigatran etexilate (Pradaxa®) associated with significantly lower rates of fatal and traumatic intracranial haemorrhage compared with Warfarin

- For Non-US, UK & Canadia Media Only
16.03.2012

Pradaxa® (dabigatran etexilate) – first new oral anticoagulant in nearly 60 years receives final NICE recommendation for stroke prevention in atrial fibrillation in the UK1

- For NON-US, NON-UK & NON- Canadian Healthcare Media Only
12.03.2012

Boehringer Ingelheim sets up its first Asian Veterinary Research & Development Center in Shanghai

02.03.2012

Porcine circovirus research projects from France and Spain awarded

29.02.2012

Boehringer Ingelheim expands capabilities in biopharmaceutical process science

21.02.2012

Boehringer Ingelheim and Xencor Enter a Collaboration Agreement for the Development, Manufacture, and Supply of Biosuperior Monoclonal Antibodies

03.02.2012

Boehringer Ingelheim, GWT and the TU Dresden sign diabetes research collaboration

31.01.2012

FDA approves Jentadueto™ (linagliptin/metformin hydrochloride) tablets for the treatment of adults with Type 2 Diabetes

- For Non-U.S. and Non-UK Media
26.01.2012

Boehringer Ingelheim launches ‘Lean-to-Clinic’ program for fast drug product supply

26.01.2012

Boehringer Ingelheim Moves into Phase III for its Head and Neck Cancer Trial Programme for Afatinib*

- FOR NON-US MEDIA ONLY
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 next